Title:
ETHANOLAMINE DERIVATIVE HAVING SYMPATHETIC ACTION AND ANTIPOLLAKIURIA ACTION
Document Type and Number:
Japanese Patent JP3282799
Kind Code:
B2
Abstract:
PROBLEM TO BE SOLVED: To obtain a new compound useful as a medicine for treating and/or preventing dysuria, convulsion or hyperanakinesia in human or animal.
SOLUTION: This compound is represented by formula I [R1 is an aryl (substituted with a halogen, OH or the like) or a heterocyclic group; R2 is H, a halogen, nitro or the like; R3 is H, an N-protecting group or the like; (n) is 0-3; bold full line is a single bond or double bond, with the proviso that when (n) is 1, R1 is a heterocyclic group (e.g. substituted with a halogen, OH, or the like) or the like or R2 is a halogen, nitro or the like or R3 is an N- protecting group or the like or bold full line is double bond], e.g. (1R,6'S)-2-[(3- ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclopenten-6-yl)amino]-1-(3- chlorophenyl)ethanol hydrochloride. The compound of formula I is obtained by reacting, e.g. a compound of formula II with a compound (salt) of formula III.
More Like This:
| JPS61251645 | NOVEL COMPOUND, MANUFACTURE AND MEDICINAL COMPOSITION |
| WO/2003/082804 | VENLAFAXINE BESYLATE |
Inventors:
Youichi Shiokawa
Masanobu Nagano
Kiyoshi Taniguchi
Kazuhiko Take
Takeshi Kato
Kazunori Tsubaki
Masanobu Nagano
Kiyoshi Taniguchi
Kazuhiko Take
Takeshi Kato
Kazunori Tsubaki
Application Number:
JP13016798A
Publication Date:
May 20, 2002
Filing Date:
May 13, 1998
Export Citation:
Assignee:
Fujisawa Pharmaceutical Co., Ltd.
International Classes:
A61K31/135; A61K31/19; A61K31/24; A61K31/275; A61K31/34; A61K31/341; A61K31/40; A61K31/403; A61K31/4035; A61K31/13; A61K31/404; A61K31/41; A61K31/42; A61K31/4245; A61K31/425; A61K31/426; A61K31/428; A61K31/433; A61K31/47; A61P7/10; A61P25/02; C07C215/08; C07C215/14; C07C215/16; C07C215/30; C07C215/64; C07C217/74; C07C219/30; C07C227/18; C07C229/16; C07C229/18; C07C229/32; C07C229/42; C07C229/44; C07C229/46; C07C235/20; C07C255/26; C07C323/25; C07D209/04; C07D209/48; C07D213/61; C07D215/12; C07D235/14; C07D253/00; C07D257/02; C07D261/08; C07D271/06; C07D271/08; C07D271/10; C07D271/12; C07D277/20; C07D277/62; C07D285/04; C07D307/52; C07D317/58; C07D487/04; C07D521/00; (IPC1-7): C07C215/30; C07C215/64; C07C217/74; C07C229/18; C07C229/42; C07C229/44; C07C323/25; C07D271/12; C07D317/58
Other References:
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，Ｖｏｌ．１１，Ｎｏ．５，１０００−１００８
Attorney, Agent or Firm:
Eiji Tabuse